Mereo BioPharma Group PLC (MREO)

NASDAQ: MREO · IEX Real-Time Price · USD
1.21 0.01 (0.83%)
Jan 25, 2022 3:59 PM EST - Market closed
Market Cap141.55M
Revenue (ttm)50.30M
Net Income (ttm)-37.13M
Shares Out116.98M
EPS (ttm)-0.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume509,224
Open1.18
Previous Close1.20
Day's Range1.11 - 1.24
52-Week Range1.05 - 4.71
Beta1.44
AnalystsStrong Buy
Price Target9.30 (+668.7%)
Earnings Daten/a

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197...

IndustryBiotechnology
Founded2015
CEODenise Pollard-Knight
Employees38
Stock ExchangeNASDAQ
Ticker SymbolMREO
Full Company Profile

Financial Performance

Financial numbers in millions GBPFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for MREO stock is "Strong Buy." The 12-month stock price forecast is 9.30, which is an increase of 668.72% from the latest price.

Price Target
$9.30
(668.72% upside)
Analyst Consensus: Strong Buy

News

Mereo BioPharma's Alvelestat Shows Improvement In COVID-19 Severity

The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO) announced topline data from a Phase 1b/2 trial of alvelestat in hospitalized COVID-19 Respiratory Disease patie...

1 month ago - Benzinga

UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitaliz...

Alvelestat reported safe and well-tolerated in patients with COVID-19

1 month ago - GlobeNewsWire

5 Penny Stocks To Buy For Under $5 This Week

5 penny stocks to buy for under $5 right now. Are they worth the risk?

Other symbols:CANFDGLYOPKPROG
1 month ago - PennyStocks

Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo's Alvelestat in Bronchiolitis Obliterans Syndrom...

LONDON and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and...

1 month ago - GlobeNewsWire

Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer

Mereo BioPharma Group plc (NASDAQ: MREO) reported interim data from ACTIVATE Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with Bristol Myers Squibb Co (NYSE: BMY) Opdivo (nivo...

1 month ago - Benzinga

Data from Investigator-sponsored Trial of Mereo BioPharma's alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Acc...

LONDON and REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and...

2 months ago - GlobeNewsWire

2 Growth Stocks That Could Deliver 1,000% Returns

These two low-priced biotech stocks could produce life-changing returns for early shareholders.

Other symbols:SENS
2 months ago - The Motley Fool

Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors

LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and...

4 months ago - GlobeNewsWire

Mereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome

Mereo BioPharma Group plc (NASDAQ: MREO) has announced data from an interim analysis of an investigator-initiated study of alvelestat, in patients with Bronchiolitis Obliterans Syndrome (BOS), following...

7 months ago - Benzinga

Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab

Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center and Mereo BioPharma Group plc (NASDAQ: MREO), has entered into a funding agreement. The partners...

8 months ago - Benzinga

Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference

LONDON and REDWOOD City, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology an...

9 months ago - GlobeNewsWire

Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights

-- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta ---- Further Strengthened Management Team ---- OncXerna Global Licensing Agreement for Navicixizumab ---- Stre...

9 months ago - GlobeNewsWire

Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference

LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

11 months ago - GlobeNewsWire

Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Und...

LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

11 months ago - GlobeNewsWire

Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares

LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

11 months ago - GlobeNewsWire

Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares

LONDON and REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

11 months ago - GlobeNewsWire

7 Penny Stocks on a Tear Right Now and Still Worth Buying

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

1 year ago - InvestorPlace

Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise

1 year ago - GlobeNewsWire

Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on ...

LONDON and REDWOOD CITY, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

1 year ago - GlobeNewsWire

Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development

LONDON and REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

1 year ago - GlobeNewsWire

Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020

LONDON and REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

1 year ago - GlobeNewsWire

Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference

LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

1 year ago - GlobeNewsWire

Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regula...

LONDON and REDWOOD CITY, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

1 year ago - GlobeNewsWire

Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020

1 year ago - GlobeNewsWire

Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update

On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020

1 year ago - GlobeNewsWire